文献速递妇科肿瘤

帕博利珠单抗联合贝伐珠单抗及口服节拍环磷酰胺治疗复发性卵巢癌的2期非随机临床试验

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项开放标签、单臂2期研究纳入40例复发性卵巢癌患者,评估帕博利珠单抗联合贝伐珠单抗及口服节拍环磷酰胺的疗效与安全性。结果显示客观缓解率为47.5%,临床获益率95.0%,中位无进展生存期10.0个月(90% CI 6.5-17.4),耐受性良好。

要点

  • 客观缓解率47.5%,其中完全缓解7.5%,部分缓解40.0%。
  • 中位无进展生存期10.0个月(90% CI 6.5-17.4)。
  • 临床获益率95.0%,持久缓解(>12个月)率25.0%。

核心结论

  • 帕博利珠单抗联合贝伐珠单抗及口服节拍环磷酰胺在复发性卵巢癌中耐受性良好,临床获益率95.0%,25.0%患者获得持久治疗反应(>12个月)。
  • 该联合方案可能成为复发性卵巢癌的未来治疗策略。

研究设计与样本

  • 开放标签、单臂2期队列研究,于2016年9月6日至2018年6月27日在美国单中心入组患者。
  • 共纳入40例复发性卵巢癌患者,其中铂耐药30例(75.0%),铂敏感10例(25.0%),平均(SD)年龄62.2(9.4)岁。
  • 患者接受静脉帕博利珠单抗200 mg和贝伐珠单抗15 mg/kg每3周一次,口服环磷酰胺50 mg每日一次,直至疾病进展、不可接受毒性或撤回知情同意。
  • 主要终点为客观缓解率(ORR)和无进展生存期(PFS),疗效评估采用irRECIST标准。

主要发现

  • 3例(7.5%)完全缓解,16例(40.0%)部分缓解,19例(47.5%)疾病稳定,客观缓解率47.5%。
  • 临床获益38例(95.0%),持久缓解10例(25.0%)。
  • 中位无进展生存期10.0个月(90% CI 6.5-17.4)。
  • 最常见3-4级治疗相关不良事件为高血压(6例[15.0%])和淋巴细胞减少(3例[7.5%])。
  • 最常报告的不良事件包括疲劳(18例[45.0%])、腹泻(13例[32.5%])和高血压(11例[27.5%])。

临床怎么用

  • 对于复发性铂敏感或铂耐药上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,可考虑帕博利珠单抗联合贝伐珠单抗及口服节拍环磷酰胺方案。
  • 治疗期间需监测高血压和淋巴细胞减少等3-4级不良事件,以及疲劳、腹泻等常见不良反应。

局限性

  • 单臂、非随机设计,无对照组,样本量较小(40例)。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable effective therapies. OBJECTIVE: To assess the efficacy and safety of a combination of pembrolizumab with bevacizumab and oral metronomic cyclophosphamide in patients with recurrent platinum-sensitive, platinum-resistant, or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer. DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-arm phase 2 cohort study enrolled patients from September 6, 2016, to June 27, 2018, at a single institution in the United States. Eligible patients had recurrent ovarian cancer, measurable disease per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST), and Eastern Cooperative Oncology Group performance status of 0 to 1. Data were analyzed from September 6, 2016, to February 20, 2020. INTERVENTIONS: Patients received intravenous pembrolizumab, 200 mg, and bevacizumab, 15 mg/kg, every 3 weeks and oral cyclophosphamide, 50 mg, once daily during the treatment cycle until disease progression, unacceptable toxic effects, or withdrawal of consent. MAIN OUTCOMES AND MEASURES: Primary outcomes were objective response rate (ORR) and progression-free survival (PFS). RESULTS: Of the 40 women enrolled, 30 (75.0%) had platinum-resistant and 10 (25.0%) had platinum-sensitive ovarian cancer with a mean (SD) age of 62.2 (9.4) years. Three women (7.5%) had complete responses, 16 (40.0%) had partial responses, and 19 (47.5%) had stable disease in response to treatment based on irRECIST criteria, with an ORR of 47.5%, clinical benefit in 38 (95.0%), and durable response in 10 (25.0%). Median PFS was 10.0 (90% CI, 6.5-17.4) months. The most common grade 3 to 4 treatment-related adverse events were hypertension (6 [15.0%]) and lymphopenia (3 [7.5%]). The most frequently reported adverse events included fatigue (18 [45.0%]), diarrhea (13 [32.5%]), and hypertension (11 [27.5%]). CONCLUSIONS AND RELEVANCE: In this phase 2 nonrandomized clinical trial, the combination of pembrolizumab with bevacizumab and oral cyclophosphamide was well tolerated and demonstrated clinical benefit in 95.0% and durable treatment responses (>12 months) in 25.0% of patients with recurrent ovarian cancer. This combination may represent a future treatment strategy for recurrent ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02853318.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Zsiros E, Lynam S, Attwood KM, et al. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2021. PMID: 33211063. doi:10.1001/jamaoncol.2020.5945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。